Ara 290

Ara 290 (Cibinetide) is an engineered 11-amino acid peptide derived from erythropoietin that activates the Innate Repair Receptor (IRR) to provide tissue-protective effects without stimulating red blood cell production. It has completed multiple Phase 2 clinical trials and holds FDA Orphan Drug status for several indications.

• Peripheral Nerve Regeneration
• Diabetic Neuropathy Treatment
• Central Nervous System Protection

Proven tissue protection, nerve regeneration, anti-inflammatory effects, excellent safety profile in clinical trials

Activates Innate Repair Receptor (IRR) through EPOR/β-common receptor complex, triggering tissue-protective signaling without erythropoietic effects

Research protocols from published literature — not dosing recommendations.

• BPC-157 — Synergistic: Both peptides promote tissue repair through complementary pathways - Ara 290 via IRR activation and BPC-157 via growth factor signaling, potentially enhancing wound healing and neuroprotection
• TB-500 — Synergistic: Combined tissue repair mechanisms may enhance recovery from injury - Ara 290 provides anti-inflammatory effects while TB-500 promotes cellular migration and angiogenesis
• Thymosin Beta-4 — Compatible: No known interactions between IRR activation and thymosin pathways, both work through different mechanisms for tissue protection and repair
• EPO (Erythropoietin) — Avoid Combination: Clinical trials exclude recent EPO use within 2 months due to potential receptor interference and unclear combined effects on hematopoiesis
• NAD+ — Monitor Combination: Both affect cellular metabolism and stress response - monitor for additive anti-inflammatory effects and potential enhanced tissue protection
• Semaglutide — Compatible: Clinical trials included patients on antidiabetic medications including GLP-1 agonists with no adverse interactions, may provide complementary metabolic benefits
• Growth Hormone — Use Caution: Both affect tissue repair and growth pathways - combination may enhance effects but requires monitoring for potential excessive growth factor activity
• Anti-TNF Biologics — Requires Timing: Clinical protocols require 6-month washout from anti-TNF therapy before Ara 290 to avoid potential immune system interactions

Supplies:

• Ara 290 lyophilized powder (4 mg vial)
• Sterile water for injection or phosphate buffer
• Sterile syringes and needles
• Alcohol swabs
• Proper lighting (protect from light)
• Refrigeration for storage

1. 1Allow vial to reach room temperature (15-20 minutes)
2. 2Clean vial top with alcohol swab
3. 3Slowly inject 1 mL sterile water into vial
4. 4Gently swirl to dissolve (do not shake vigorously)
5. 5Solution may appear slightly cloudy - this is normal
6. 6Use immediately or store at 2-8°C for up to 24 hours
7. 7Protect from light during storage and use
8. 8Rotate injection sites (anterior thigh recommended)

Week 1-2: Initial anti-inflammatory effects, potential mild improvement in pain symptoms. Week 2-4: Progressive nerve regeneration, improved tissue healing markers, enhanced wound healing if applicable. Week 4-6: Peak therapeutic effects, maximum nerve fiber density improvements, sustained pain relief. Month 2-6: Long-lasting benefits continue due to "molecular switch" effect, sustained tissue protection.

Excellent safety profile in clinical trials with no serious drug-related adverse events. No anti-drug antibodies detected in human studies. No hematopoietic effects or risk of polycythemia unlike erythropoietin. Contraindicated with recent anti-TNF therapy (within 6 months) or EPO use (within 2 months). Monitor for injection site reactions and rotate injection sites. Not recommended during pregnancy or in patients with BMI >34 kg/m².

Excellent safety profile in clinical trials with no serious drug-related adverse events. No anti-drug antibodies detected in human studies. No hematopoietic effects or risk of polycythemia unlike erythropoietin. Contraindicated with recent anti-TNF therapy (within 6 months) or EPO use (within 2 months). Monitor for injection site reactions and rotate injection sites. Not recommended during pregnancy or in patients with BMI >34 kg/m².

Ara 290 should be stored at Powder: -80°C long-term, 4°C medium-term; Reconstituted: use immediately or refrigerate up to 24 hours.